Sage Journals: Discover world-class research

Abstract

KIAA1199 (also known as CEMIP or HYBID), an archived gene listed in the Human Unidentified Gene-Encoded (HUGE) database, has been implicated in tumor progression and metastasis in a wide range of cancers, including breast, cervical, cholangiocarcinoma, pancreatic, colorectal, gastric, hepatocellular, lung, ovarian, prostate, papillary thyroid, and brain cancers. Overexpression of KIAA1199 is significantly correlated with poor prognosis and metastasis and has been clinically associated with chemoresistance. In addition, KIAA1199 may serve as a novel biomarker for cancer diagnosis and prognosis, particularly due to its role in maintaining cancer stem cell properties. However, the molecular mechanisms by which KIAA1199 regulates chemoresistance, prognosis, and cancer stem cell development remain incompletely understood. Therefore, this review aims to summarize the clinical relevance of KIAA1199 as a novel regulator involved in chemoresistance, cancer prognosis, and cancer stem cell biology.

Keywords

KIAA1199 chemoresistance prognosis cancer drug resistance cancer stem cells

Introduction

KIAA1199 (CEMIP, HYBID), a 150 Kda protein encoded by a gene located on chromosome 15q25.1, is an archived gene listed in the Human Unidentified Gene-Encoded (HUGE) protein database.¹ KIAA1199 was initially described in association with nonsyndromic hearing loss,² as well as with cancer initiation and progression,³ osteoarthritis and rheumatoid arthritis,⁴ atherosclerosis,⁵ and idiopathic pulmonary fibrosis.⁶ To date, the HUGE database includes more than 2400 entries, conventionally designated with the prefix “KIAA” followed by a four-digit number, beginning with KIAA0001.⁷ KIAA1199 was first investigated as a protein of unknown function in 1999,¹ and later identified as an inner ear–specific protein in 2003.² It localizes to the cytoplasm,⁸ particularly around the perinuclear region in the endoplasmic reticulum.⁹ Importantly, KIAA1199 detected in cell culture media is a secreted protein rather than a transmembrane protein.³

The KIAA1199 protein consists of 136 amino acids and includes 3 domains and an N-terminal secretion signal sequence. These domains comprise 2 GG domains and 1 G8 domain. The GG domain, approximately 100 amino acids in length and composed of 7 β-strands and 2 α-helices, is involved in hyaluronic acid binding and/or degradation. This is supported by evidence showing that a single mutation in the first GG domain impairs hyaluronidase activity.^2,4 The G8 domain contains 8 conserved glycine residues and 5 consecutive β-strand pairs. While most G8-containing proteins are predicted to be intra- or transmembrane proteins, the G8 domain of KIAA1199 may contribute to its localization.⁸ The N-terminal signal sequence, consisting of 30 amino acids, is responsible for directing the protein into the secretory pathway. Therefore, both the GG and G8 domains are essential to unravel the functional role of KIAA1199.

Gene expression of KIAA1199 is regulated by both genetic and epigenetic mechanisms. Its promoter region contains binding sites for 2 key transcription factors, NF-_KB and AP-1, and its basal promoter activity is influenced by the DNA methylation status of a CpG island within the first intron.¹⁰ In addition, H3K4 trimethylation (H3K4me3), an active transcription marker, enhances KIAA1199 expression,¹¹ whereas H3K27 trimethylation (H3K27me3), a repressive mark, leads to its silencing.¹² Furthermore, H3K4me3 and H3K27me3 modifications occur at both promoter and enhancer regions but with distinct functional roles. H3K4me3 is primarily associated with active promoters and enhancers while H3K27me3 is often found at repressed promoters and enhancer.^13-15 Several microRNAs such including miR-600, miR-216a, miR-29c-3p, miR-140-5p, miR-4656, miR-486-5p,… have been known to significantly regulate KIAA1199 expression.^3,16-20 Moreover, pro-inflammatory cytokines such as interleukin-1β also induce KIAA1199 transcription.²¹

Overexpression of KIAA1199 has been observed in multiple cancers, including breast,¹⁰ non-small cell lung,^22,23 colorectal,^24,25 gastric,^26,27 hepatocellular,^28,29 prostate,³⁰ papillary thyroid,¹⁷ pancreatic,³¹ ovarian,³² and cholangiocarcinoma.³³ Clinically, it might be involved in chemoresistance in various cancers, such as colorectal,^34-36 hepatocellular,³⁷ non-small cell lung,³⁸ and gastric cancer.³⁹ Furthermore, KIAA1199 is a significant indicator of poor prognosis in breast,^40,41 cervical,⁴² cholangiocarcinoma,³³ pancreatic,³¹ colorectal,^16,43,44 gastric,^26,45 hepatocellular,^28,29 lung,^22,23 ovarian,^32,46,47 prostate,^30,48,49 papillary thyroid,^17,50 and brain cancers.⁵¹ Notably, KIAA1199 is also considered a potential regulator of cancer stem cell progression in colorectal cancer.¹⁶ In this review, we summarize the critical relevance of KIAA1199 as a novel regulator in cancer progression, chemoresistance, prognosis, and cancer stem cell development.

KIAA1199 and Progression of Cancer

Cancer proliferation, 1 of the 5 main steps of metastasis, is a fundamental process in which a single transformed cell undergoes rapid division, acquires genetic heterogeneity, and prepares for dissemination.⁵² During this progression, KIAA1199 plays 3 critical roles: (i) modulating cell signaling transduction, (ii) regulating the cell cycle, and (iii) driving metabolic reprogramming, all of which contribute to cancer cell growth and survival. In terms of signaling, KIAA1199 activates key pathways such as EGFR, MEK/ERK, PI3K/AKT, Wnt/β-catenin, and STAT3. In regulating the cell cycle, KIAA1199 either facilitates progression or induces arrest, depending on context. For metabolism, KIAA1199 promotes glycolysis, glutamine metabolism, and amino acid biosynthesis, thus supporting the energy and biosynthetic demands of rapidly proliferating cells.⁵³

KIAA1199 Drives Cancer Cell Proliferation by Modulating Key Cell Signaling Transduction

KIAA1199 enhances cancer cell proliferation by modulating critical cell signaling transductions including EGFR, MEK/ERK, PI3K/AKT, Wnt/β-catenin, and STAT3:

EGFR pathway: KIAA1199 protects cells from Semaphorin 3A-mediated apoptosis by binding to its receptor Plexin A2 and stimulating EGFR signaling, sustaining proliferation and survival in cervical cancer.⁴²

MEK/ERK pathway: In BRAF^V600E-mutated colorectal cancer, KIAA1199 binds MEK1/2, enhancing their phosphorylation along with ERK1/2 and RSK1, thereby promoting proliferation and survival.³⁴

PI3K/AKT pathway: Knockdown of KIAA1199 reduces phosphorylated and total levels of PI3K, AKT, P70S6K, and BCL-2, thus inhibiting growth and promoting apoptosis in ovarian cancer.^32,46

Wnt/β-catenin pathway: Silencing KIAA1199 downregulates β-catenin, c-myc, cyclin D1 and MMPs in gastric^24,27 and colorectal cancers.⁵⁴ Elevated nuclear KIAA1199 correlates with increased nuclear β-catenin.⁵⁴

STAT3 pathway: KIAA1199 induces the ER chaperone GRP78, which activates STAT3 signaling, promoting proliferation and migration in breast cancer.^55,56

KIAA1199 Drives Cancer Cell Proliferation by Regulating Cell Cycle

Knockdown of KIAA1199 induces G0/G1-phase arrest and downregulates cyclin D1 in hepatocellular carcinoma.²⁸ In ovarian cancer, KIAA1199 knockdown causes S-phase arrest, with decreased expression of cyclin A and CDK2.³²

KIAA1199 Drives Cancer Cell Proliferation by Metabolic Reprogramming

KIAA1199 enhances cancer cell proliferation via metabolic reprogramming by promoting glycolysis, glutamine metabolism, and amino acid biosynthesis:

Glycolysis: KIAA1199 activates AMPK, which inhibits GSK3β, stabilizes β-catenin, and upregulates PDK4-mediated glycolysis. Inhibition of PDK4 reduces VEGF, suggesting therapeutic potential in prostate cancer.⁴⁸

Glutamine metabolism: KIAA1199 functions as an O-GlcNAcylation adapter protein then KIAA1199 alters glutamine metabolism by enhancing O-GlcNAcylation of β-catenin which translocate to the nucleus to promote the overexpression of KIAA1199, glutaminase 1 and glutamine transporters (SLC1A5 and SLC38A2). Therefore, co-targeting KIAA1199 and glutamine metabolism suppresses proliferation and metastasis in colorectal cancer.⁵⁷ Moreover, in small cell lung cancer, KIAA1199 stabilizes nuclear c-Myc by preventing its degradation through FBXW7 and stabilized C-Myc enhances the expression of the SLC1A5 driving glutamine-dependent tumor growth.⁵⁸ Therefore, KIAA1199 promotes glutamine-dependent growth via FBXW7/c-Myc regulation in small cell lung cancer.⁵⁸

Amino acid biosynthesis: Through ERK activation, KIAA1199 upregulates Myc, enhancing biosynthesis of amino acids, fatty acids, and proteins. These processes support cancer cell proliferation and activate the mTOR pathway.³⁴

KIAA1199 and Chemoresistance

Overcoming intrinsic and acquired chemoresistance remains a major challenge in the treatment of cancer patients, often leading to recurrence, dissemination, and mortality.⁵⁹ The molecular mechanisms underlying chemoresistance include transporter pumps, oncogene activation, tumor suppressor gene inactivation, mitochondrial alterations, DNA repair mechanisms, autophagy, epithelial-mesenchymal transition (EMT), cancer stemness, and exosomes.^59-61 KIAA1199 has been shown to play a clinical role in regulating chemoresistance in various cancers, including colorectal,^34-36 hepatocellular,³⁷ non-small cell lung,³⁸ and gastric cancer.³⁹ Furthermore, KIAA1199 is involved in the regulation of multiple cell signaling transductions as Wnt/β-catenin,^24,27,54 EGFR,⁴² MEK/ERK,³⁴ PI3K/AKT,^32,46 and STAT3.^55,56 Therefore, KIAA1199 represents a novel target for controlling chemoresistance in cancer.

The RAF/MEK/ERK pathway is crucial in tumor progression.^59-62 Several clinical trials have investigated the effects of allosteric MEK1/2 inhibitors, such as selumetinib, in combination with traditional chemotherapeutics. These include a phase II trial combining FOLFOX and erlotinib as first-line therapy for metastatic colorectal cancer,^60-63 and a phase II trial of selumetinib plus irinotecan as second-line therapy for KRAS-mutated colorectal cancer.^61-64 Notably, selumetinib also overcomes ITGA2-induced 5-fluorouracil (5-FU) resistance in colorectal cancer.^62-65 Importantly, KIAA1199 has been found in endosomes and binds MEK1 to sustain ERK1/2 activation in selumetinib-resistant BRAF^V600E-mutated colorectal cancer.³⁴ Additionally, KIAA1199-dependent pathway maintained c-Myc through ERK1/2 and provided metabolic advantage in resistant cells; and KIAA1199 silencing circumvented resistance to MEK1 inhibition, party, through a decrease of both ERK1/2 signaling and c-Myc.³⁴

Oxaliplatin is a key chemotherapeutic agent for colorectal cancer, functioning by inducing cancer cell apoptosis through the formation of platinum-DNA adducts.^66,67 However, drug resistance significantly limits its efficacy and remains a major challenge in colorectal cancer treatment.⁶⁸ Mechanisms of oxaliplatin resistance include enhanced DNA repair, evasion of apoptosis, activation of NF-_KB signaling, and altered drug transport.⁶⁹ Furthermore, O-GlcNAcylation is a unique form of post-translational protein modification involving the attachment of a single N-acetylglucosamine molecule to serine or threonine residues. This modification responds dynamically to cellular stress, hormonal changes, or nutrient availability by reversible addition or removal of sugar moieties on proteins. Thousands of nuclear and cytoplasmic proteins have been shown to undergo O-GlcNAcylation, which influences transcription, translation, signaling, the cell cycle, and other physiological processes.⁷⁰ It is increasingly recognized for its role in diabetes, neurodegeneration, cardiovascular disease, cancer, and has potential in diagnostics and therapeutics. KIAA1199 promotes O-GlcNAcylation of proteins via bridging O-GlcNAc transferase and substrate protein.⁵⁷ A study of Hua et al demonstrated that KIAA1199 is upregulated in oxaliplatin-resistant colorectal cancer cells compared to parental cells. KIAA1199 prevents apoptosis by alleviating endoplasmic reticulum (ER) stress via enhanced protein O-GlcNAcylation.³⁵ Furthermore, KIAA1199 sustains EMT and promotes colorectal cancer metastasis by O-GlcNAcylation of SNAI1.³⁵ It also acts as an immune suppressor, enabling colorectal cancer cells to escape immune surveillance,^71,72 and contributes to immunotherapy resistance by suppressing pyroptosis through the DNMT1/GSDME pathway.³⁶

Sorafenib is the first targeted therapy approved for advanced hepatocellular carcinoma. It inhibits tumor cell proliferation mainly via targeting the Raf/MEK/ERK signaling pathway and exerts antiangiogenic effects through inhibition of VEGFR-2/3 and PDGFR-β tyrosine kinases.⁷³ Although sorafenib has shown clinical benefit in hepatocellular carcinoma, long-term exposure frequently results in acquired drug resistance.^74,75 A study by Xu et al demonstrated that KIAA1199 expression was significantly elevated in both sorafenib-resistant hepatocellular carcinoma cell lines (in vitro) and xenograft models (in vivo). KIAA1199 promotes sorafenib resistance by enhancing the migratory and invasive capabilities of hepatocellular carcinoma cells.³⁷ Additionally, KIAA1199 contributes to sorafenib resistance and cell migration through modulation of the EGF-induced EMT process.³⁷ Furthermore, a study by Liu et al. demonstrated that KIAA1199, closely associated with lung metastasis, promoted pre-metastatic niche formation by increasing lung matrix stiffness and upregulated serum KIAA1199 was indicative of lung fibrotic changes severity in patients with hepatocellular carcinoma-lung metastasis.⁷⁶ Pirfenidone, an inhibitor of the TGF-β signaling pathway,^77-79 inhibits KIAA1199/TGF-β1/Smad signaling pathway and reduces lung metastases stiffening⁷⁶; Especially, pirfenidone in combination with sorafenib effectively suppresses the incidence of lung metastasis compared with sorafenib alone.⁷⁶ These findings suggest that KIAA1199 may serve as a novel therapeutic target for overcoming sorafenib resistance and inhibiting metastasis in hepatocellular carcinoma.

Paclitaxel remains a cornerstone in the treatment of advanced non-small cell lung cancer.^80,81 However, the development of paclitaxel resistance severely reduces its therapeutic efficacy. Mechanisms contributing to this resistance include upregulation of ATP-binding cassette (ABC) transporters, activation of pro-survival signaling pathways, induction of EMT,⁸² and dysregulation of epigenetic regulators.⁸³ Recent studies have shown that ALKBH5 expression is reduced in paclitaxel-resistant non-small cell lung cancer cell.³⁸ Overexpression of ALKBH5 in these resistant cells suppresses proliferation, increases paclitaxel sensitivity, and reverses EMT.³⁸ Importantly, KIAA1199 is a downstream target of ALKBH5, and the ALKBH5/KIAA1199 axis plays a pivotal role in modulating the EMT process suggesting that KIAA1199 regulates cancer cell sensitivity to paclitaxel in non-small cell lung cancer.³⁸ Furthermore, a study by Shen et al. demonstrated that in small cell lung cancer, KIAA1199 expression positively correlates with IC₅₀ values of chemotherapeutic agents as cisplatin, etoposide…, and KIAA1199 functions as an adaptor protein to interact with SRC and YAP enhancing their activation and nuclear signaling activity therefore combination of dasatinib (SRC inhibitor) or verteportin (YAP inhibitor) and cisplatin or etoposide displayed excellent synergistic antitumor effect in vitro and in vivo, suggesting KIAA1199/SRC/YAP complex is a potential strategy for small cell lung cancer patients.⁸⁴

5-Fluorouracil (5-FU), a first-line chemotherapeutic agent for gastric cancer, inhibits cancer cell proliferation, migration, and invasion by promoting DNA damage-induced apoptosis.^85,86 Moreover, combining apatinib or ramucirumab with 5-FU produces synergistic effects in suppressing metastasis and proliferation via the VEGFR-2/AKT/ERK1/2 pathway.⁸⁷ ZNF281, a novel biomarker associated with chemotherapy response, also influences sensitivity to 5-FU through the Wnt/β-catenin signaling pathway.⁸⁷ KIAA1199 has been identified as a prognostic marker in locally advanced gastric cancer patients who receive postoperative adjuvant chemotherapy with S-1.³⁹ Knockdown of KIAA1199 suppresses proliferation, invasiveness, and enhances the sensitivity of gastric cancer cells to 5-FU.³⁹ Therefore, KIAA1199 represents a novel therapeutic target in the pharmacologic treatment of gastric cancer.

KIAA1199 and Prognosis of Cancer

Prognosis of cancer refers to the prediction and evaluation of the likely course of the disease, potential recovery, and survival duration. Clinically, prognosis is influenced by factors such as tumor size, stage, grade, lymph node involvement, patient age, and treatment response.^88,89 KIAA1199 has been identified as a significant indicator of high metastatic potential and poor prognosis across multiple cancer types, including breast,^40,41 cervical,⁴² cholangiocarcinoma,³³ pancreatic,³¹ colorectal,^16,43,44 gastric,^26,45 hepatocellular,^28,29 lung,^22,23 ovarian,^42,46,47 prostate,^30,48,49 papillary thyroid,^17,50 and brain cancer.⁵¹ Thus, KIAA1199 holds promise as a prognostic biomarker in human malignancies.

KIAA1199 is upregulated in invasive breast cancer specimens and in the highly invasive MDA-MB-231 cell line, whereas its expression is minimal in non-invasive MCF-7 cells.¹⁰ KIAA1199 levels are higher in breast cancer tissue than in adjacent normal tissue,⁴¹ and patients expressing KIAA1199 exhibit significantly shorter overall and disease-free survival compared to non-expressers. Contributing factors for KIAA1199 overexpression in breast cancer include TP53 mutation, DNA hypomethylation, and transcriptional regulation by EZH2, EGR1, and JUN.⁴¹ These findings support the role of KIAA1199 as both a prognostic and metastatic biomarker and as a potential therapeutic target.

KIAA1199 is aberrantly expressed in human papillomavirus (HPV)-infected cells and in clinical samples of cervical (pre)neoplastic lesions.⁴² It binds Plexin A2 and protects cells from Semaphorin 3A-induced apoptosis by promoting EGFR stability and signaling.⁴² As an EGFR-binding protein, KIAA1199 deficiency impairs EGF-dependent phosphorylation of Src, MEK1, and ERK1/2. KIAA1199 also promotes EGF-mediated EMT,⁴² characterizing it as an oncogenic protein induced by HPV infection and sustained NF-_KB activation, which transmits pro-survival and invasive signals via EGFR signaling.

KIAA1199 is overexpressed in cholangiocarcinoma, and higher levels are associated with shorter overall and disease-free survival.³³ KIAA1199 enhances tumor growth and metastasis in cholangiocarcinoma.³³ Additionally, expression of EMT-related components in the TGF-β pathway is significantly altered upon upregulation or silencing of KIAA1199.³³ These findings highlight KIAA1199 as a promising prognostic marker and therapeutic target in cholangiocarcinoma.

In pancreatic ductal adenocarcinoma, KIAA1199 expression is significantly higher than in adjacent non-tumor tissues.³¹ Patients with high KIAA1199 expression exhibit markedly shorter overall survival. Both KIAA1199 expression and The Union for International Cancer Control (UICC) stage are independent predictors of poor prognosis,³¹ suggesting that overexpression of KIAA1199 contributes to disease progression and reduced post-surgical survival.

In colorectal cancer, KIAA1199 expression has been extensively studied across different tumor stages. In normal colonic mucosa, protein expression is restricted to the lower portions of intestinal crypts areas of physiological Wnt activity but is markedly upregulated in adenomas,^90,91 colorectal cancer,⁹² and stage I–IV adenocarcinomas.⁹³ In stage III and combined stage II plus III cases, 5-year overall survival is significantly better in patients with low KIAA1199-expressing tumors compared to those with high expression.⁴³ Furthermore, KIAA1199 expression correlates with tumor invasion depth, TNM stage, and poor prognosis.⁴⁴ Silencing KIAA1199 suppresses colorectal cancer cell migration and invasion in vitro, and inhibits metastasis in vivo.¹⁶ These findings support KIAA1199 as a clinically relevant prognostic biomarker and therapeutic target in colorectal cancer.

KIAA1199 is highly expressed in gastric cancer and has been associated with prognosis and lymph node metastasis.²⁶ KIAA1199 is also significantly upregulated in gastric cancer and is linked to disease progression.⁹⁴ High KIAA1199 expression is more common in advanced stages and correlates with poorer outcomes.⁹⁵ Furthermore, patients with high KIAA1199 levels have significantly shorter overall survival than those with low expression,⁴⁵ supporting its role as a prognostic biomarker in gastric cancer.

KIAA1199 expression is significantly elevated in hepatocellular carcinoma tissues compared to adjacent non-tumor tissues.^28,29 High KIAA1199 levels are associated with reduced disease-free and overall survival.²⁸ Its expression also correlates with larger tumor size and metastasis.²⁹ In vitro, KIAA1199 knockdown reduces cell proliferation and migration, while in vivo, it suppresses tumorigenesis and lung metastasis.²⁹ These findings suggest that KIAA1199 is a biomarker of poor prognosis in hepatocellular carcinoma .

In non-small cell lung cancer, KIAA1199 expression is significantly higher in tumor tissues than in normal lung tissue.²² Its high expression is associated with poor differentiation, lymph node metastasis, and advanced nodal stage.¹⁹ Elevated KIAA1199 levels predict poorer overall survival.^22,23 Mechanistically, KIAA1199 modulates EMT by affecting the expression of EMT markers, transcription factors, and signaling pathways.²³ Specifically, KIAA1199 promotes invasion and migration through PI3K-Akt–mediated EMT, establishing it as an independent prognostic biomarker in non-small cell lung cancer.

In ovarian cancer, KIAA1199 expression is higher in tumor tissues than in normal ovaries.³² Its knockdown significantly impairs tumor cell proliferation, migration, and invasion.³² KIAA1199 induces chemoresistance and metastasis by activating the PI3K/AKT/mTOR pathway.^32,46 It also enhances VEGFA expression and MMP activity, facilitating angiogenesis and cell migration.³² Furthermore, ovarian cancer patients with low expression of KIAA1199 had a significantly higher 5-year survival rate than those with high expression; and the expression of KIAA1199, STAT3 and p-STAT3 increased after IL-6 stimulation showing that KIAA1199 is transcriptionally activated by IL6/STAT3 pathway; suggesting that KIAA1199 could be used as a poor prognosis factor and potential target in treatment.⁴⁷

KIAA1199 expression is minimal in normal prostate epithelial (PrEC) cells and non-invasive LNCaP prostate cancer cells.⁸ In contrast, it is markedly elevated in prostate cancer tissues and cells.^10,30,48 High KIAA1199 expression correlates with tumor stage, overexpression of hypoxia-inducible factor 1α (HIF-1α), and increased angiogenesis.³⁰ It promotes angiogenesis and vasculogenic mimicry through enhanced secretion.³⁰ Additionally, KIAA1199 facilitates anoikis resistance and metastasis by activating PDK4-dependent metabolic reprogramming.⁴⁸ Furthermore, the correlation between the KIAA1199 expression and clinicopathological characteristics was analyzed, showing a positive correlation with the clinical prostate cancer stages (I + II vs III + IV, P = 0.0025) and the metastatic prostate PC-3 and DU145 cells exhibited the highest expression level among several well-known cell lines with varying metastatic potential (RWPE-1, LNCaP, 22RV1, PC-3, and DU145).⁴⁹ These findings support that KIAA1199 could be used as a poor prognosis factor and potential target in treatment of prostate cancer.

In papillary thyroid carcinoma, KIAA1199 expression is significantly upregulated in papillary thyroid carcinoma tissue compared with normal tissue.^17,50 Papillary thyroid carcinoma cells (TPC-1, KTC-1, CAL62, K1) showed higher expression of KIAA1199 than Htori-3 cells.⁵⁰ Additionally, KIAA1199 expression is positively correlated with more advanced clinicopathological characteristics.^17,50 KIAA1199 promotes cancer cell migration and invasion, and its silencing suppresses these functions by inhibiting EMT both in vitro and in vivo.^17,50 Furthermore, knockdown of KIAA1199 suppressed papillary thyroid carcinoma cell growth and metastasis through PDK4-mediated inactivation of STAT3/AKT/NF-kB.⁵⁰ These findings support that KIAA1199 could be used as a poor prognosis factor and potential target in treatment of thyroid cancer.

KIAA1199 is also highly expressed in brain metastases compared to adjacent brain stroma and non-brain metastatic lesions.⁴⁵ Its expression correlates with reduced survival, and high KIAA1199 levels in primary tumors are associated with rapid metastatic progression to the brain.⁵¹ Thus, KIAA1199 serves as a potential prognostic biomarker and therapeutic target in brain metastasis.

KIAA1199 and Cancer Stem Cells

Cancer stem cells are a subpopulation of cancer cells that exhibit properties like normal stem or progenitor cells, including self-renewal and multilineage differentiation. Cancer stem cells drive tumor growth and heterogeneity, suggesting that cancer stem cells can differentiate through adaptation to the tumor microenvironment and in response to therapeutic pressures, thereby contributing to a heterogeneous tumor phenotype.⁹⁶

In colorectal cancer, KIAA1199 shows higher expression in metastatic CD44⁺ cancer stem cells than in adjacent non-tumorous tissue.¹⁶ Its expression positively correlates with the number of circulating tumor cells and an interstitial phenotype.¹⁶ KIAA1199 also maintains c-Myc protein levels through ERK1/2 signaling, conferring a metabolic advantage in selumetinib-resistant colorectal cancer organoids ex vivo. Knockdown of KIAA1199 sensitizes these organoids to MEK1 inhibition by reducing ERK1/2 activation and c-Myc expression.³⁴

Furthermore, KIAA1199 is highly enriched in brain metastasis–derived small extracellular vesicles and has been shown to promote pre-metastatic niche formation and cancer cell colonization in the brain by upregulating cytokine expression.⁵¹ As cells undergoing EMT acquire cancer stem cells-like properties,⁹⁷ and given that KIAA1199 strongly promotes EMT, its deficiency results in a dramatic reduction of the cancer stem cell pool (defined as CD44⁺/CD24^- cells). Moreover, sphere formation under stem cell culture conditions is significantly dependent on KIAA1199.^40,42 Collectively, this evidence highlights that the cancer stem cell population critically depends on KIAA1199.

Conclusion and Future Perspectives

KIAA1199 (also known as CEMIP or HYBID), a key member of the Human Unidentified Gene-Encoded (HUGE) database, is considered a novel regulator of chemoresistance, prognosis and cancer stem cells in various types of cancer. In the present review, we briefly summarize how the abnormal expression of KIAA1199 is significantly associated with chemoresistance, prognosis and cancer stem cell in human cancer.

Preclinical and clinical studies designed to evaluate different therapeutic strategies could improve the ability to treat human cancer patients by inhibiting KIAA1199 in combination with chemotherapy or targeted therapy. In addition, KIAA1199 could be utilized as a clinical regulator to control chemoresistance, prognosis and cancer stem cell (Figure 1). Overall, significant future advances in these areas of precision medicine targeting KIAA1199 could be clinically meaningful and enhance the treatment efficacy for human cancer.

Figure 1.

The Clinical Role of KIAA1199 in Human Cancer. KIAA1199 Regulates Several Hallmarks of Cancer as a Clinical Regulator to Control Chemoresistance, Prognosis and Cancer Stem Cells. β-Catenin Binds TCF/LEF to Drive KIAA1199 to Induce Higher Expression of KIAA1199 which is Responsible for Significant Activation of the Ras/Raf/MEK1/ERK1/2 Signaling Pathway in Regulation of Chemoresistance, Prognosis and Cancer Stem Cell

Footnotes

ORCID iD

Hong-Quan Duong

Author Contributions

HQD, TNLD and VLN conceived the concept and wrote the manuscript. TTPP, VTL, TND critically revised the manuscript for intellectual content. HQD organized and revised the final version of the manuscript. Data authentication is not applicable. All authors have read and approved the final manuscript.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Foundation for Science and Technology Development (NAFOSTED; grant no. 108.06-2020.03) (H.Q.D).

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

Nagase

Ishikawa

Kikuno

Hirosawa

Nomura

Ohara

. Prediction of the coding sequences of unidentified human genes.XV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 1999;6(5):337-345.

Abe

Usami

Nakamura

. Mutations in the gene encoding KIAA1199 protein, an inner-ear protein expressed in Deiters' cells and the fibrocytes, as the cause of nonsyndromic hearing loss. J Hum Genet. 2003;48(11):564-570.

Liu

Yan

Han

Tian

. The emerging role of KIAA1199 in cancer development and therapy. Biomed Pharmacother. 2021;138:111507.

Yoshida

Nagaoka

Kusaka-Kikushima

, et al. KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding protein involved in hyaluronan depolymerization. Proc Natl Acad Sci U S A. 2013;110(14):5612-5617.

Xue

Wang

Deng

Huang

Tian

. CEMIP regulates the proliferation and migration of vascular smooth muscle cells in atherosclerosis through the WNT-beta-catenin signaling pathway. Biochem Cell Biol. 2020;98(2):249-257.

Kwapiszewska

Gungl

Wilhelm

, et al. Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis. Eur Respir J. 2018;52(5):1800564.

Kikuno

Nagase

Nakayama

, et al. HUGE: a database for human KIAA proteins, a 2004 update integrating HUGEppi and ROUGE. Nucleic Acids Res. 2004;32(Database issue):D502-504.

Michishita

Garcés

Barrett

Horikawa

. Upregulation of the KIAA1199 gene is associated with cellular mortality. Cancer Lett. 2006;239(1):71-77.

Evensen

Kuscu

Nguyen

, et al. Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in cancer cell migration. J Natl Cancer Inst. 2013;105(18):1402-1416.

10.

Kuscu

Evensen

Kim

Zucker

Cao

. Transcriptional and epigenetic regulation of KIAA1199 gene expression in human breast cancer. PLoS One. 2012;7(9):e44661.

11.

Evensen

Kuscu

, et al. Hypoxia promotes colon cancer dissemination through up-regulation of cell migration-inducing protein (CEMIP). Oncotarget. 2015;6(24):20723-20739.

12.

Hsieh

Wang

, et al. H3K27me3 loss plays a vital role in CEMIP mediated carcinogenesis and progression of breast cancer with poor prognosis. Biomed Pharmacother. 2020;123:109728.

13.

Liu

Wang

Liu

, et al. Distinct features of H3K4me3 and H3K27me3 chromatin domains in pre-implantation embryos. Nature. 2016;537(7621):558-562.

14.

Calo

Wysocka

. Modification of enhancer chromatin: what, how, and why? Mol Cell. 2013;49(5):825-837.

15.

Wei

Zhu

, et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4⁺ T cells. Immunity. 2009;30(1):155-167.

16.

Zhang

Zhao

Shen

, et al. Down-regulation of KIAA1199/CEMIP by miR-216a suppresses tumor invasion and metastasis in colorectal cancer. Int J Cancer. 2017;140(10):2298-2309.

17.

Jiao

Wang

Yin

Zhang

Cheng

. KIAA1199, a target of MicoRNA-486-5p, promotes papillary thyroid cancer invasion by influencing epithelial-mesenchymal transition (EMT). Med Sci Monit. 2019;25:6788-6796.

18.

Wang

, et al. The miR-29c-KIAA1199 axis regulates gastric cancer migration by binding with WBP11 and PTP4A3. Oncogene. 2019;38(17):3134-3150.

19.

Wang

Lin

Gao

. Functional role of long non-coding RNACASC19/miR-140-5p/CEMIP axis in colorectal cancer progression in vitro. World J Gastroenterol. 2019;25(14):1697-1714.

20.

. Long noncoding RNA HCP5 promotes prostate cancer cell proliferation by acting as the sponge of miR4656 to modulate CEMIP expression. Oncol Rep. 2020;43(1):328-336.

21.

Kohi

Sato

Koga

Matayoshi

Hirata

. KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer. Oncotarget. 2017;8(10):17156-17163.

22.

Deng

Lei

Zhang

Huang

. Overexpression of KIAA1199: an independent prognostic marker in non-small cell lung cancer. J Cancer Res Therapeut. 2017;13(4):664-668.

23.

Tang

Ding

Shen

, et al. KIAA1199 promotes invasion and migration in non-small-cell lung cancer (NSCLC) via PI3K-Akt mediated EMT. J Mol Med (Berl). 2019;97(1):127-140.

24.

Birkenkamp-Demtroder

Maghnouj

Mansilla

, et al. Repression of KIAA1199 attenuates Wnt-signalling and decreases the proliferation of colon cancer cells. Br J Cancer. 2011;105(4):552-561.

25.

Zhao

Zhang

Shen

, et al. KIAA1199 promotes metastasis of colorectal cancer cells via microtubule destabilization regulated by a PP2A/stathmin pathway. Oncogene. 2019;38(7):935-949.

26.

Matsuzaki

Tanaka

Mimori

Tahara

Inoue

. Clinicopathologic significance of KIAA1199 overexpression in human gastric cancer. Ann Surg Oncol. 2009;6(7):2042-2051.

27.

Jia

Wang

, et al. KIAA1199 promotes migration and invasion by Wnt/β-catenin pathway and MMPs mediated EMT progression and serves as a poor prognosis marker in gastric cancer. PLoS One. 2017;12(4):e0175058.

28.

Jiang

Zhai

Shi

Luo

Jin

. KIAA1199 overexpression is associated with abnormal expression of EMT markers and is a novel independent prognostic biomarker for hepatocellular carcinoma. OncoTargets Ther. 2018;11:8341-8348.

29.

Liu

Han

Gong

, et al. Knockdown of KIAA1199 attenuates growth and metastasis of hepatocellular carcinoma. Cell Death Discov. 2018;4:102.

30.

Luo

Yang

Zhang

. HIF1α lactylation enhances KIAA1199 transcription to promote angiogenesis and vasculogenic mimicry in prostate cancer. Int J Biol Macromol. 2022;222(Pt B):2225-2243.

31.

Koga

Sato

Kohi

, et al. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. Pancreatology. 2017;17(1):115-122.

32.

Shen

Zong

Liu

Chen

Sheng

Zhao

. CEMIP promotes ovarian cancer development and progression via the PI3K/AKT signaling pathway. Biomed Pharmacother. 2019;14:108787.

33.

Zhai

Wang

, et al. Serum KIAA1199 is an advanced-stage prognostic biomarker and metastatic oncogene in cholangiocarcinoma. Aging (Albany NY). 2020;12(23):23761-23777.

34.

Duong

Nemazanyy

Rambow

, et al. The endosomal protein CEMIP links WNT signaling to MEK1-ERK1/2 activation in selumetinib-resistant intestinal organoids. Cancer Res. 2018;78(16):4533-4548.

35.

Hua

Wang

, et al. KIAA1199 promotes oxaliplatin resistance and epithelial mesenchymal transition of colorectal cancer via protein O-GlcNAcylation. Transl Oncol. 2023;28:101617.

36.

Zhao

Zhou

, et al. Targeting pyroptosis reverses KIAA1199-mediated immunotherapy resistance in colorectal cancer. J Immunother Cancer. 2025;13(2):e010000.

37.

, et al. KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program. Cancer Lett. 2019;454:78-89.

38.

Gao

Qiao

, et al. ALKBH5 regulates paclitaxel resistance in NSCLC via inhibiting CEMIP-mediated EMT. Toxicol Appl Pharmacol. 2024;483:116807.

39.

Oneyama

Sakamoto

Oue

, et al. Clinical significance of KIAA1199 as a novel target for gastric cancer drug therapy. Anticancer Res. 2019;39(12):6567-6573.

40.

Xue

Zhu

Qiao

, et al. CEMIP as a potential biomarker and therapeutic target for breast cancer patients. Int J Med Sci. 2022;19(3):434-445.

41.

Dong

Yang

Yuan

Hou

. High expression of CEMIP correlates poor prognosis and the tumur microenvironment in breast cancer as a promisingly prognostic biomarker. Front Genet. 2021;12:768140.

42.

Shostak

Zhang

Hubert

, et al. NF-κB-induced KIAA1199 promotes survival through EGFR signalling. Nat Commun. 2014;5:5232.

43.

Fink

Myeroff

Kariv

, et al. Induction of KIAA1199/CEMIP is associated with colon cancer phenotype and poor patient survival. Oncotarget. 2015;6(31):30500-30515.

44.

Liu

Wang

, et al. Association between KIAA1199 overexpression and tumor invasion, TNM stage, and poor prognosis in colorectal cancer. Int J Clin Exp Pathol. 2015;8(3):2909-2918.

45.

Guo

Yang

Liu

, et al. Prognostic marker identification based on weighted gene co-expression network analysis and associated in vitro confirmation in gastric cancer. Bioengineered. 2021;12(1):4666-4680.

46.

Ediriweera

Tennekoon

Samarakoon

. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance. Semin Cancer Biol. 2019;59:147-160.

47.

Qin

Gao

, et al. KIAA1199 induces advanced biological behavior and development of ovarian cancer through activation of the IL-6/STAT3 pathway. Biocell. 2021;46(3):689-697.

48.

Zhang

Song

Sun

, et al. AMPK/GSK3β/β-catenin cascade-triggered overexpression of CEMIP promotes migration and invasion in anoikis-resistant prostate cancer cells by enhancing metabolic reprogramming. FASEB J. 2018;32(7):3924-3935.

49.

Liu

, et al. ATF4/CEMIP/PKCα promotes anoikis resistance by enhancing protective autophagy in prostate cancer cells. Cell Death Dis. 2022;13(1):46.

50.

Zhou

Hua

Sun

. Cell migration inducing hyaluronidase 1 promotes growth and metastasis of papillary thyroid carcinoma. Bioengineered. 2022;13(5):11822-11831.

51.

Rodrigues

Hoshino

Kenific

, et al. Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 2019;21(11):1403-1412.

52.

Welch

Hurst

. Defining the hallmarks of metastasis. Cancer Res. 2019;79(12):3011-3027.

53.

Vander Heiden

Cantley

Thompson

. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033.

54.

Liang

Fang

Yang

Song

. Silencing of CEMIP suppresses Wnt/β-catenin/Snail signaling transduction and inhibits EMT program of colorectal cancer cells. Acta Histochem. 2018;120(1):56-63.

55.

Chen

Zhang

. Cell migration inducing hyaluronidase 1 (CEMIP) activates STAT3 pathway to facilitate cell proliferation and migration in breast cancer. J Recept Signal Transduct Res. 2021;41(2):145-152.

56.

Hernandez

Cohen

. Linking cell-surface GRP78 to cancer: from basic research to clinical value of GRP78 antibodies. Cancer Lett. 2022;524:1-14.

57.

Hua

Zhang

, et al. CEMIP, a novel adaptor protein of OGT, promotes colorectal cancer metastasis through glutamine metabolic reprogramming via reciprocal regulation of β-catenin. Oncogene. 2021;40(46):6443-6455.

58.

Shen

, et al. CEMIP promotes small cell lung cancer proliferation by activation of glutamine metabolism via FBXW7/c-Myc-dependent axis. Biochem Pharmacol. 2023;209:115446.

59.

Zheng

. The molecular mechanisms of chemoresistance in cancers. Oncotarget. 2017;8(6):59950-59964.

60.

Brasseur

Gévry

Asselin

. Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget. 2017;8(3):4008-4042.

61.

Shervington

. Chemoresistance in gliomas. Mol Cell Biochem. 2008;312(1-2):71-80.

62.

Peyssonnaux

Eychène

. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93(1-2):53-62.

63.

Meyerhardt

Stuart

Fuchs

, et al. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer. Ann Oncol. 2007;18(7):1185-1189.

64.

Hochster

Uboha

Messersmith

, et al. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015;75(1):17-23.

65.

Qin

Lou

, et al. Selumetinib overcomes ITGA2-induced 5-fluorouracil resistance in colorectal cancer. Int Immunopharmacol. 2024;137:11287.

66.

Rottenberg

Disler

Perego

. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 2021;21(1):37-50.

67.

Mattia

Cecchin

Toffoli

. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy. Drug Resist Updates. 2015;20:39-70.

68.

Crea

Nobili

Paolicchi

, et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updates. 2011;14(6):280-296.

69.

Nussinov

Tsai

Jang

. Anticancer drug resistance: an update and perspective. Drug Resist Updates. 2021;59:100796.

70.

Peng

Zhu

Zhang

, et al. Regulation of the Hippo-YAP pathway by glucose sensor O-GlcNAcylation. Mol Cell. 2017;68(3):591-604.e5.

71.

Wang

Zhang

, et al. KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration. Hepatology. 2022;76(4):967-981.

72.

Zhang

Hua

, et al. Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation. J Immunother Cancer. 2023;11(1):e005592.

73.

Tang

Chen

Zhang

, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Targeted Ther. 2020;51(1):87.

74.

Cheng

Kang

Chen

, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34.

75.

Shimoda

Yoshida

Mizuno

, et al. Hyaluronan-binding protein involved in hyaluronan depolymerization controls endochondral ossification through hyaluronan metabolism. Am J Pathol. 2017;187(5):1162-1176.

76.

Liu

Xie

Zhang

, et al. Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases. Cell Death Dis. 2023;14(1):25.

77.

Oku

Shimizu

Kawabata

, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590(1-3):400-408.

78.

Liu

Drew

Gaugler

Cheng

Visner

. Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. Am J Transplant. 2005;5(6):1256-1263.

79.

Dosanjh

Ikonen

Wan

Morris

. Pirfenidone: a novel anti-fibrotic agent and progressive chronic allograft rejection. Pulm Pharmacol Therapeut. 2002;15(5):433-437.

80.

Herbst

Morgensztern

Boshoff

. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446-454.

81.

Singh

Hassanabad

. Non-small cell lung cancer: emerging molecular targeted and immunotherapeutic agents. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188636.

82.

Kavallaris

. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10(3):194-204.

83.

Gao

Assaraf

Chen

Wang

. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updates. 2021;57:100770.

84.

Shen

Wei

, et al. Adaptor protein CEMIP reduces the chemosensitivity of small cell lung cancer via activation of an SRC-YAP oncogenic module. Acta Pharmacol Sin. 2024;45(12):2657-2671.

85.

Lei

Dong

, et al. Metal-fluorouracil networks with disruption of mitochondrion enhanced ferroptosis for synergistic immune activation. Theranostics. 2022;12(14):6207-6222.

86.

Fan

Zhai

, et al. Docetaxel and 5-FU enhanced the inhibitory effects of apatinib and ramucirumab on growth and migration of gastric cancer. Life Sci. 2022;296:120439.

87.

Zhou

Wang

Xin

Xiao

Qin

. Identification and validation of the role of ZNF281 in 5-fluorouracil chemotherapy of gastric cancer. J Cancer Res Clin Oncol. 2024;150(6):307.

88.

Weeks

Cook

O’Day

, et al. Relationship between cancer patients’ predictions of prognosis and their treatment preferences. JAMA. 1998;279(21):1709-1714.

89.

Untch

Bonner

Roggin

, et al. Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors. J Gastrointest Surg. 2014;18(3):457-462.

90.

Sabates-Bellver

Van der Flier

De Palo

, et al. Transcriptome profile of human colorectal adenomas. Mol Cancer Res. 2007;5(12):1263-1275.

91.

Galamb

Spisák

Sipos

, et al. Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br J Cancer. 2010;102(4):765-773.

92.

Tiwari

Schneider

Fiorino

, et al. Early insights into the function of KIAA1199, a markedly overexpressed protein in human colorectal tumors. PLoS One. 2013;8(7):e69473.

93.

Lapointe

Pedersen

Dunne

, et al. Discovery and validation of molecular biomarkers for colorectal adenomas and cancer with application to blood testing. PLoS One. 2012;7(1):e29059.

94.

Economescu

Necula

Dragu

, et al. Identification of potential biomarkers for early and advanced gastric adenocarcinoma detection. Hepatogastroenterology. 2010;57(104):1453-1464.

95.

Zhang

Jia

Jiang

. KIAA1199 and its biological role in human cancer and cancer cells (review). Oncol Rep. 2014;31(4):1503-1508.

96.

Ayob

Ramasamy

. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25(1):20.

97.

Mani

Guo

Liao

, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704-715.

KIAA1199: A Novel Regulator of Chemoresistance in Human Cancer Cells

Abstract

Keywords

Introduction

KIAA1199 and Progression of Cancer

KIAA1199 Drives Cancer Cell Proliferation by Modulating Key Cell Signaling Transduction

KIAA1199 Drives Cancer Cell Proliferation by Regulating Cell Cycle

KIAA1199 Drives Cancer Cell Proliferation by Metabolic Reprogramming

KIAA1199 and Chemoresistance

KIAA1199 and Prognosis of Cancer

KIAA1199 and Cancer Stem Cells

Conclusion and Future Perspectives

Footnotes

ORCID iD

Author Contributions

Funding

Declaration of Conflicting Interests

References